Quadrant Management

Vantem Global streamlines the construction process, lowering costs and shortening delivery times.

Wandercraft develops and sells the first exoskeleton to walk self-balanced, providing a realistic gait without crutches or technical aids. Its first commercial version, Atalante, was CE-marked in 2019 and is sold to European rehab hospitals to improve gait re-learning treatments. As of June 2020, FDA approval is on the way. The company develops a slimmer, sleeker and agile Personal Mobility exo for daily life usage. Wandercraft is a full-stack company integrating competencies in algorithmics, AI, robotics, production, clinical, marketing and sales. Wandercraft's exo is the first realistic, autonomous walking device for the walking impaired and also likely the first bipedal walking robot to be a commercial product and not a lab prototype.

SyncThink is a leading neuro-technology company with foundational IP in eye-tracking analytics and devices. The Company was founded in 2009 by Dr. Jamshid Ghajar, Neurosurgeon, founder of the Brain Trauma Foundation and director of the Stanford Concussion and Brain Performance center. SyncThink is headquartered in Palo Alto, CA with an affiliate office in New York City. Highlights of the Company include: - World Class Partnerships: Partnered/affiliated with leading research institutions and practitioners including the Brain Trauma Foundation (“BTF”), Stanford University, Mass General Hospital and the Pac-12. - Millions in R&D: SyncThink and BTF have successfully secured over $36 million in technology development and research contracts from US Department of Defense since 2008. - Numerous Applications with FDA Approval: Initial focus on neuro-diagnostics (primarily concussions) in military and athletics. Broader set of potential applications include attention development in children,, enhancing brain performance, fatigue evaluation, pharmacuetical, among others. The EYE-SYNC device has been FDA approved. - Proprietary Software Technology: Eleven issued patents (with additional six patents pending) covering hardware, analytics, market applications and scientific platform. TECHNOLOGY The EYE-SYNC device is a fully-integrated, head-mounted eye-tracking device for rapid, reliable screening of attention focus. The device is non-invasive, low-risk, and highly reliable. As a subject tracks a predictable moving target that follows a circular trajectory on a screen within the head mounted device, eye movements are recorded by high speed cameras. Embedded systems software characterizes eye-target synchronization and the results are displayed and stored on a handheld peripheral for instant concussion screening. The benefits of the EYE-SYNC technology are speed (takes less than 60 seconds), accuracy, portability, and proven metrics.

SyncThink is a leading neuro-technology company with foundational IP in eye-tracking analytics and devices. The Company was founded in 2009 by Dr. Jamshid Ghajar, Neurosurgeon, founder of the Brain Trauma Foundation and director of the Stanford Concussion and Brain Performance center. SyncThink is headquartered in Palo Alto, CA with an affiliate office in New York City. Highlights of the Company include: - World Class Partnerships: Partnered/affiliated with leading research institutions and practitioners including the Brain Trauma Foundation (“BTF”), Stanford University, Mass General Hospital and the Pac-12. - Millions in R&D: SyncThink and BTF have successfully secured over $36 million in technology development and research contracts from US Department of Defense since 2008. - Numerous Applications with FDA Approval: Initial focus on neuro-diagnostics (primarily concussions) in military and athletics. Broader set of potential applications include attention development in children,, enhancing brain performance, fatigue evaluation, pharmacuetical, among others. The EYE-SYNC device has been FDA approved. - Proprietary Software Technology: Eleven issued patents (with additional six patents pending) covering hardware, analytics, market applications and scientific platform. TECHNOLOGY The EYE-SYNC device is a fully-integrated, head-mounted eye-tracking device for rapid, reliable screening of attention focus. The device is non-invasive, low-risk, and highly reliable. As a subject tracks a predictable moving target that follows a circular trajectory on a screen within the head mounted device, eye movements are recorded by high speed cameras. Embedded systems software characterizes eye-target synchronization and the results are displayed and stored on a handheld peripheral for instant concussion screening. The benefits of the EYE-SYNC technology are speed (takes less than 60 seconds), accuracy, portability, and proven metrics.